Ozempic

(Semaglutide)

ApprovedPeptide

Semaglutide is used to help people with type 2 diabetes control their blood sugar levels, and it's also used for weight loss in people who are overweight or obese. It works by helping your body use insulin better and reducing your appetite.[2] Ozempic is currently approved and in use across 95 indications[4].[1]

Ozempic is one of 1347 peptide programs targeting NASH/MASH. It is currently in Approved.

Indications

526

Total Trials

Active Trials

1,346

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

NASH/MASHApproved

Weight LossActive, not recruiting

Atrial FibrillationSuspended

ObesityActive, not recruiting

Type 1 DiabetesRecruiting

Non-Alcoholic Fatty Liver DiseaseCompleted

SemaglutideNot yet recruiting

Endothelial DysfunctionActive, not recruiting

Insulin SecretionActive, not recruiting

Obstructive Sleep ApneaActive, not recruiting

NASH/MASHApproved

Approved

Weight LossApproved

Active, not recruiting

Atrial FibrillationApproved

Suspended

ObesityApproved

Active, not recruiting

Type 1 DiabetesPhase 3

Recruiting

Non-Alcoholic Fatty Liver DiseasePhase 2

Completed

SemaglutideApproved

Not yet recruiting

Endothelial DysfunctionApproved

Active, not recruiting

Insulin SecretionPreclinical

Active, not recruiting

Obstructive Sleep ApneaPreclinical

Active, not recruiting

Showing 10 of 95 indications

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

2 2

Biltricide

Bayer

Preclinical

4 3

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 4

Theo-Dur

Pfizer

Preclinical

1 5

Minipress

Pfizer

Preclinical

1 6

Niclocide

Bayer

Preclinical

1 7

Emtriva

Gilead

Preclinical

1 8

Lamprene

Novartis

Preclinical

1 9

Foscavir

CClinigen, Inc.

Preclinical

6 10

Sirturo

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Weight Loss

NCT06633783

Post-ApprovalRecruiting

Prediabetes

NCT05119179

N/ANot yet recruiting

Obesity

NCT07319975

Not yet recruiting

Endometrial Cancer

NCT07462663

Phase 3Active, not recruiting

Type 2 Diabetes Mellitus

NCT06778967

Phase 3Not yet recruiting

Type 2 Diabetes

NCT07139548

Clinical

Trials by Indication[1]

Type 2 Diabetes55 trials

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03018028·243 enrolled

A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03989232·961 enrolled

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Withdrawn· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06083675

Show 52 more trials

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02773381·15 enrolled

A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02212067·87 enrolled

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05394519·1,200 enrolled

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01885208·813 enrolled

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT01923181·632 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)

Completed· Novo Nordisk logo

Novo Nordisk··NCT03648281·333 enrolled

Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

Recruiting·GGT Metabolic Solutions, Inc.·N/A·NCT07317115·20 enrolled

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

Not yet recruiting·GGuangdong Raynovent Biotech Co., Ltd·Phase 3·NCT07139548·600 enrolled

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02827708·324 enrolled

Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05950516·478 enrolled

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06403761·158 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT04094415·581 enrolled

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT05443334·465 enrolled

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT05316662·187 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)

Completed· Novo Nordisk logo

Novo Nordisk··NCT03929679·218 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT04067999·230 enrolled

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01686945·107 enrolled

A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05813912·148 enrolled

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02648204·1,201 enrolled

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02254291·308 enrolled

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT05443191·50 enrolled

A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment

Completed· Novo Nordisk logo

Novo Nordisk··NCT06478550·304 enrolled

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

Active, not recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06184568·349 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)

Completed· Novo Nordisk logo

Novo Nordisk··NCT04261933·789 enrolled

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03552757·1,210 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)

Completed· Novo Nordisk logo

Novo Nordisk··NCT03631186·215 enrolled

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02207374·601 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT03457012·462 enrolled

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT05486065·245 enrolled

A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

Recruiting·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 3·NCT07064486·477 enrolled

A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02147431·38 enrolled

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT05144984·500 enrolled

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06323174·189 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)

Completed· Novo Nordisk logo

Novo Nordisk··NCT04083820·521 enrolled

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01930188·1,231 enrolled

Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

Completed· Novo Nordisk logo

Novo Nordisk··NCT06351748·34,238 enrolled

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02607865·1,864 enrolled

Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT05533632·104 enrolled

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03136484·788 enrolled

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02054897·388 enrolled

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05649137·512 enrolled

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

Withdrawn· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05444153

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02305381·397 enrolled

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03689374·2,274 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)

Completed· Novo Nordisk logo

Novo Nordisk··NCT03876015·215 enrolled

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

Active, not recruiting·—··NCT06980623·26,000 enrolled

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT04153929·413 enrolled

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06260722·1,250 enrolled

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03191396·577 enrolled

Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk··NCT06507475·209 enrolled

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01720446·3,297 enrolled

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT04601740·145 enrolled

Semaglutide35 trials

Semaglutide and Intestinal Iron Absorption

Completed·UUniversity Hospital Dubrava·N/A·NCT06629688·51 enrolled

A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02845219·25 enrolled

Effects of Semaglutide on Nicotine Intake

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT05530577·24 enrolled

Show 32 more trials

Semaglutide for Helping Opioid Recovery

Recruiting·—·Phase 2·NCT06639464·46 enrolled

A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05996874·121 enrolled

Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02249871·54 enrolled

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05646706·1,407 enrolled

Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02249910·32 enrolled

A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04228354·28 enrolled

Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02172313·78 enrolled

DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

Not yet recruiting·—·Phase 4·NCT07483801·112 enrolled

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04097600·274 enrolled

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

Completed·SSabyasachi Sen·Phase 4·NCT04126603·10 enrolled

Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02060266·7 enrolled

A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06699329·38 enrolled

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04878406·24 enrolled

Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02231684·42 enrolled

Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02557620·113 enrolled

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02022254·24 enrolled

The Effects of Semaglutide on Body Composition and Performance in Military Personnel

Withdrawn·—·Phase 4·NCT06468748

Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01866748·170 enrolled

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02920385·45 enrolled

A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02064348·168 enrolled

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05766709·53 enrolled

A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03010475·41 enrolled

Semaglutide in CFRD

Completed·UUniversity of Minnesota·Phase 2/3·NCT05788965·8 enrolled

16-week Flexible vs. 8-week Semaglutide Titration

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 3·NCT04447859·100 enrolled

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05890976·200 enrolled

Semaglutide Therapy for Alcohol Reduction - Tulsa

Completed·OOklahoma State University Center for Health Sciences·Phase 2·NCT05891587·80 enrolled

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02146079·44 enrolled

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02070510·52 enrolled

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03611582·611 enrolled

Effect Of Semaglutide In Coronary Atheroma Plaque

Unknown status·FFundación Instituto de Estudios de Ciencias de la Salud de Castilla y León·Phase 3·NCT05071417·120 enrolled

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06041217·242 enrolled

Latino Semaglutide Study

Completed·LLoma Linda University·Phase 3·NCT05087342·119 enrolled

Overweight14 trials

A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04187300·68 enrolled

Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.

Recruiting·FFundacion Dexeus·Phase 4·NCT07242534·62 enrolled

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT04102189·201 enrolled

Show 11 more trials

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03574584·37 enrolled

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03548987·902 enrolled

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03707990·88 enrolled

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT05822830·751 enrolled

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03693430·304 enrolled

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03548935·1,961 enrolled

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT04251156·375 enrolled

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05751226·88 enrolled

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04940078·40 enrolled

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03811574·401 enrolled

A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

Recruiting·SShanghai World Leader Pharmaceutical Co., Ltd.·Phase 1·NCT07465965·60 enrolled

Type 2 Diabetes Mellitus12 trials

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Not yet recruiting· Novo Nordisk logo

Novo Nordisk··NCT05689372·600 enrolled

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02906930·703 enrolled

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03086330·302 enrolled

Show 9 more trials

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03951753·117 enrolled

A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Unknown status·GGan and Lee Pharmaceuticals, USA·Phase 2·NCT06256549·272 enrolled

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT06579105·406 enrolled

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

Active, not recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT06778967·1,100 enrolled

A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04515849·248 enrolled

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02863328·822 enrolled

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03021187·731 enrolled

Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Completed·—·Phase 4·NCT06475586·30 enrolled

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Unknown status·RRenJi Hospital·N/A·NCT05779644·300 enrolled

Obesity12 trials

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06131437·809 enrolled

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06745284·60 enrolled

Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07293325·66 enrolled

Show 9 more trials

Anti-obesity Pharmacotherapy and Inflammation

Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled

Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

Not yet recruiting·—·N/A·NCT07319975·48 enrolled

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

Terminated· Pfizer logo

Pfizer·Phase 1·NCT05671653·32 enrolled

A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

Enrolling by invitation· Novo Nordisk logo

Novo Nordisk··NCT07081178·555 enrolled

The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT04263415·30 enrolled

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03842202·72 enrolled

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT05579249·500 enrolled

Semaglutide in Treatment of Obesity

Active, not recruiting·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 3·NCT06604624·462 enrolled

A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

Recruiting·HHangzhou Sciwind Biosciences Co., Ltd.·Phase 2·NCT07073417·160 enrolled

53 more indications

Weight loss6 trials

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06780449·400 enrolled

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT06571383·500 enrolled

A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

Not yet recruiting·HHangzhou Jiuyuan Gene Engineering Co. Ltd.,·Phase 3·NCT06633783·370 enrolled

Show 3 more trials

WEgovy Real World Assessment of Weight Loss in Korea

Enrolling by invitation· Novo Nordisk logo

Novo Nordisk··NCT07280221·500 enrolled

Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

Completed·HHillel Yaffe Medical Center··NCT07043361·5,300 enrolled

Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

Recruiting·PProf. Dr. Martin Wabitsch··NCT07302802·70 enrolled

Body Weight4 trials

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06388187·300 enrolled

Protein Supplementation Intervention on Body Weight

Recruiting·CChinese Academy of Sciences·N/A·NCT06989203·140 enrolled

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06207877·62 enrolled

Show 1 more trial

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05813925·331 enrolled

Type 1 Diabetes3 trials

Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

Recruiting·UUniversity of Washington·Phase 2·NCT05822609·60 enrolled

GLP-1 RA for Stage 1 Type 1 Diabetes

Not yet recruiting·—·Phase 2·NCT07430332·15 enrolled

ADJUnct Semaglutide Treatment in Type 1 Diabetes

Completed·—·Phase 2·NCT05537233·115 enrolled

Heart Failure3 trials

Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

Completed·—··NCT06914141·28,118 enrolled

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

Completed·—··NCT06914102·58,387 enrolled

Mechanisms of Semaglutide Therapy in Heart Failure Patients

Recruiting·UUniversity Medical Centre Ljubljana·Phase 1/2·NCT06541509·10 enrolled

Alcohol Use Disorder2 trials

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

Recruiting·YYale University·Phase 2·NCT07040592·30 enrolled

Semaglutide for Alcohol Use Disorder

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT05520775·48 enrolled

Myocardial Infarction2 trials

Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction

Not yet recruiting·UUniversity of Sao Paulo General Hospital·Phase 4·NCT06557811·88 enrolled

Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

Recruiting·IInstituto Mexicano del Seguro Social·Phase 3·NCT07295223·44 enrolled

Hepatitis2 trials

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05877547·381 enrolled

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

Completed· Gilead logo

Gilead·Phase 2·NCT03987074·109 enrolled

Hepatic Impairment2 trials

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02016911·56 enrolled

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02210871·44 enrolled

Atorvastatin2 trials

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06289504·34 enrolled

Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02243098·31 enrolled

Cardiovascular2 trials

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

Completed·—··NCT07096063·887,132 enrolled

Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

Enrolling by invitation·—·Phase 4·NCT06959784·142 enrolled

Fatty Liver Disease2 trials

Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Not yet recruiting·IInstitut universitaire de cardiologie et de pneumologie de Québec, University Laval·N/A·NCT06764056·120 enrolled

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT03987451·71 enrolled

Renal Impairment1 trial

Effect of Renal Impairment on the Pharmacokinetics of NN9535

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00833716·62 enrolled

Biomarkers1 trial

GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

Recruiting·FFederico II University·Phase 4·NCT07314684·80 enrolled

Dialysis1 trial

DIALYSIS-TIR Study

Active, not recruiting·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT06042153·43 enrolled

Oral1 trial

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06097390·121 enrolled

Gastrointestinal Disease1 trial

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02877355·55 enrolled

Concentration1 trial

A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03466567·21 enrolled

Metabolic Disease1 trial

The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

Withdrawn·CCorEvitas··NCT06354101

Major Depressive Disorder1 trial

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

Completed·UUniversity Health Network, Toronto·Phase 2·NCT04466345·72 enrolled

Stroke1 trial

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

Completed·—·Phase 2·NCT05920889·140 enrolled

Tobacco Use1 trial

Impact of Semaglutide on Tobacco Use and Related Health Behaviors

Recruiting·UUniversity of Oklahoma·Phase 4·NCT06986993·40 enrolled

Type 2 Diabetic Patients1 trial

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

Unknown status·UUniversity Hospital Sestre Milosrdnice·Phase 4·NCT06243536·60 enrolled

Diabetes Mellitus1 trial

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT02453711·957 enrolled

Clinical Trial1 trial

A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00813020·44 enrolled

Gastric Emptying1 trial

Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02079870·30 enrolled

Trial1 trial

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03144271·58 enrolled

Chronic Kidney Disease1 trial

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT04865770·106 enrolled

Peripheral Arterial Disease1 trial

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT04560998·792 enrolled

Double-blind1 trial

A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01766245·28 enrolled

Drug Repurposing1 trial

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Completed·—··NCT05768945·742,670 enrolled

Liver Disease1 trial

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06409130·270 enrolled

Impaired Renal Function1 trial

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02014259·71 enrolled

Tics1 trial

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01272973·96 enrolled

PreDiabetes1 trial

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 4·NCT05119179·300 enrolled

Motor Function1 trial

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

Active, not recruiting·MMayo Clinic·Phase 4·NCT06801015·30 enrolled

Drug1 trial

Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00851773·84 enrolled

Heart Disease1 trial

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03574597·17,604 enrolled

Methamphetamine1 trial

Glutide for Ending Methamphetamine

Not yet recruiting·SSan Francisco Department of Public Health·Phase 2·NCT07204249·162 enrolled

Schizophrenia1 trial

Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

Recruiting·CCentre for Addiction and Mental Health·N/A·NCT05333003·92 enrolled

Children1 trial

Promoting Healthy Children and Youth

Not yet recruiting·UUniversity of Minnesota·Phase 4·NCT06977438·1,020 enrolled

Insulin Secretion1 trial

Exercise and GLP-1 RA on Insulin Secretion

Unknown status·UUniversity of Copenhagen·N/A·NCT04383197·30 enrolled

Endometrial Cancer1 trial

SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer

Not yet recruiting·HHospital Universitari de Bellvitge··NCT07462663·82 enrolled

Pathophysiology1 trial

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

Active, not recruiting·RRegion Skane·Phase 2·NCT04451837·200 enrolled

Cardiovascular Disease1 trial

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Recruiting·SSteno Diabetes Center Copenhagen·Phase 3·NCT06082063·2,000 enrolled

Weight Change1 trial

Comparison of Body Weight Change Through Different Smeglutide Administration Methods

Unknown status·HHuashan Hospital·Phase 4·NCT05616052·80 enrolled

Chronic1 trial

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Completed·VVeru Inc.·Phase 2·NCT06282458·168 enrolled

Coronary Artery Disease1 trial

Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes

Recruiting·NNational Institute of Cardiology, Warsaw, Poland·Phase 4·NCT07254572·300 enrolled

Alcohol Use Disorder (AUD)1 trial

Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)

Completed·UUniversity of Colorado, Denver·Phase 2·NCT05892432·50 enrolled

Alzheimer's Disease1 trial

Oral Semaglutide in Patients With Alzheimer's Disease

Not yet recruiting·IImperial College London·Phase 2·NCT07200622·60 enrolled

Smoking Cessation1 trial

Semaglutide for Post-Smoking Cessation Weight Management

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT06173778·197 enrolled

Ischemic stroke1 trial

Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

Not yet recruiting·RRenJi Hospital·Phase 3·NCT07030621·436 enrolled

Outcome1 trial

GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

Recruiting·VVanderbilt University Medical Center·Phase 1·NCT06338553·24 enrolled

Unspecified1 trial

Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01619345·27 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 5, 2017

OZEMPIC

NDA NDA209637

Jun 4, 2021

WEGOVY

NDA NDA215256

Dec 9, 2024

RYBELSUS

NDA NDA213051

Dec 22, 2025

WEGOVY

NDA NDA218316

Sources

References

[1]
ClinicalTrials.gov — 526 trial records for Semaglutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Ozempic drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Semaglutide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Semaglutide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA218316). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Ozempic. U.S. Food & Drug Administration.
[7]
PubMed — 7 publications indexed for Semaglutide. U.S. National Library of Medicine.
[8]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: GLP-1 Receptor Agonist[3]
Modality: Peptide[3]
Highest Phase: Approved[1]
Company: Novo Nordisk

Patent Landscape[6]

Patent Cliff

Feb 27, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10357616Jan 20, 2026

9616180Jan 20, 2026

9861757Jan 20, 2026

10376652Jan 20, 2026

9108002Jan 20, 2026

36 more patents

8536122Mar 20, 2026

9775953Jul 17, 2026

10220155Jul 17, 2026

11097063Jul 17, 2026

8920383Jul 17, 2026

RE46363Aug 3, 2026

9687611Feb 27, 2027

9457154Sep 29, 2027

8129343Dec 5, 2031

10960052Dec 16, 2031

10086047Dec 16, 2031

9278123Dec 16, 2031

11382957Dec 16, 2031

9132239Feb 1, 2032

11759501Mar 15, 2033

10933120Mar 15, 2033

11759502Mar 15, 2033

11759503Mar 15, 2033

12594326Mar 15, 2033

11033499Jun 19, 2033

9764003Jun 21, 2033

10335462Jun 21, 2033

10278923May 2, 2034

12239739May 2, 2034

12514822May 2, 2034

12569543Apr 28, 2037

11752198Aug 24, 2038

12214017Aug 24, 2038

10888605Aug 24, 2038

12295988Oct 10, 2038

12551536Oct 10, 2038

12029779Oct 10, 2038

11833248Feb 1, 2039

12396953Feb 1, 2039

11478533May 13, 2040

11318191Feb 17, 2041

Key Publications[7]

Semaglutide in Chronic Kidney Disease: FLOW Trial Results

N Engl J MedMay 24, 2024DOI: 10.1056/NEJMoa2403347

Semaglutide and MASH: Phase 3 Histological Outcomes

N Engl J MedMar 14, 2024DOI: 10.1056/NEJMoa2311203

Oral Semaglutide Versus Injectable GLP-1 Receptor Agonists: A Systematic Review

Lancet Diabetes EndocrinolOct 15, 2023DOI: 10.1016/S2213-8587(23)00263-1

Semaglutide Effects on Heart Failure Outcomes in Obesity: SELECT Trial

N Engl J MedDec 28, 2022DOI: 10.1056/NEJMoa2215256

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

N Engl J MedNov 10, 2022DOI: 10.1056/NEJMoa2215760

Once-Weekly Semaglutide in Adults with Overweight or Obesity

N Engl J MedJun 2, 2022DOI: 10.1056/NEJMoa2206038

Semaglutide 2.4 mg and Cardiometabolic Risk Reduction: STEP Program Results

JAMAFeb 10, 2021DOI: 10.1001/jama.2021.1831

Ozempic

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Type 2 Diabetes55 trials

Semaglutide35 trials

Overweight14 trials

Type 2 Diabetes Mellitus12 trials

Obesity12 trials

Weight loss6 trials

Body Weight4 trials

Type 1 Diabetes3 trials

Heart Failure3 trials

Alcohol Use Disorder2 trials

Myocardial Infarction2 trials

Hepatitis2 trials

Hepatic Impairment2 trials

Atorvastatin2 trials

Cardiovascular2 trials

Fatty Liver Disease2 trials

Renal Impairment1 trial

Biomarkers1 trial

Dialysis1 trial

Oral1 trial

Gastrointestinal Disease1 trial

Concentration1 trial

Metabolic Disease1 trial

Major Depressive Disorder1 trial

Stroke1 trial

Tobacco Use1 trial

Type 2 Diabetic Patients1 trial

Diabetes Mellitus1 trial

Clinical Trial1 trial

Gastric Emptying1 trial

Trial1 trial

Chronic Kidney Disease1 trial

Peripheral Arterial Disease1 trial

Double-blind1 trial

Drug Repurposing1 trial

Liver Disease1 trial

Impaired Renal Function1 trial

Tics1 trial

PreDiabetes1 trial

Motor Function1 trial

Drug1 trial

Heart Disease1 trial

Methamphetamine1 trial

Schizophrenia1 trial

Children1 trial

Insulin Secretion1 trial

Endometrial Cancer1 trial

Pathophysiology1 trial

Cardiovascular Disease1 trial

Weight Change1 trial

Chronic1 trial

Coronary Artery Disease1 trial

Alcohol Use Disorder (AUD)1 trial

Alzheimer's Disease1 trial

Smoking Cessation1 trial

Ischemic stroke1 trial

Outcome1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Key Publications[7]

Related News